Sanofi (NASDAQ:SNY) Shares Gap Up – Here’s Why

Shares of Sanofi (NASDAQ:SNY) gapped up prior to trading on Tuesday . The stock had previously closed at $45.89, but opened at $47.65. Sanofi shares last traded at $47.85, with a volume of 453,757 shares traded.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of research reports. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

The firm has a market capitalization of $123.95 billion, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $50.84 and a 200-day moving average price of $52.09.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period in the previous year, the firm earned $2.55 earnings per share. Sanofi’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post 4.06 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently bought and sold shares of SNY. POM Investment Strategies LLC purchased a new position in Sanofi during the 2nd quarter worth $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the third quarter valued at $29,000. Concord Wealth Partners raised its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp bought a new position in Sanofi during the 2nd quarter worth about $35,000. Finally, Fortitude Family Office LLC grew its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.